FierceBiotech

Roche to pick up LumiraDx’s point-of-care tests through $350M deal

Roche has a plan to build out its point-of-care diagnostic catalog, with the goal of delivering more tests to homes, pharmacies, doctor’s offices and elsewhere. The company aims to acquire a selection ...
MobiHealthNews

LumiraDx to sell point of care technology platform to Roche for $295M

Diagnostics company LumiraDx announced it signed an agreement to sell its point-of-care technology to pharma giant Roche for $295 million, with an additional payment of $55 million to fund the ...
Nasdaq

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care technology combining multiple diagnostic modalities on a single platform

Basel, 29 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx’s ...
Nasdaq

Roche (RHHBY) to Acquire LumiraDx's Point of Care Technology

Roche RHHBY announced that it entered into a definitive agreement to acquire LumiraDx's LMDX Point of Care technology, combining multiple diagnostic modalities on a single platform. Based in the U.K., ...
Morningstar

Sapphiros announces a strategic agreement with Roche, providing Roche access to 1 billion lateral flow tests and access to future molecular point-of-care tests

Agreement secures rapid, global access to tests for future pandemics and health emergencies Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros' 5 billion unit ...
technologynetworks

Roche Receives FDA Clearance With CLIA Waiver for Its First Molecular Point-of-Care Test

Roche announced that its first point-of-care test for the detection of Bordetella infections, including whooping cough (pertussis), has been granted U.S. Food and Drug Administration (FDA) 510(k) ...